Deep learning identifies MYT1L as a regulator that restricts glioblastoma plasticity
scDORI inferred enhancer-linked regulatory networks from single-cell multiome data and prioritized regulators for perturbation. MYT1L overexpression restricted alternative cell states and reduced tumor growth and invasion in mice; loss of MYT1L restored malignant features. This is preclinical evidence, not an established treatment. The result was public in a May 13, 2025 preprint; the peer-reviewed paper appeared November 4, 2026.
Technology: scDORI; deep learning for enhancer-linked gene-regulatory network inference
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Patient-derived cell perturbations and mouse xenograft experiments tested inferred regulators.
- Still unknown: Clinical benefit and independent follow-up replication were not established by this review.
- AI role: Deep network inference nominated regulatory programs and MYT1L for experimental testing.
Evidence sources: https://www.nature.com/articles/s41586-026-11177-0 · https://www.biorxiv.org/content/10.1101/2025.05.13.653733v1
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.